Local bacteria affect the efficacy of chemotherapeutic drugs

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Lehouritis, Panos ^a   Cummins, Joanne ^a   Stanton, Michael ^a   Murphy, Carola T ^a   McCarthy, Florence O ^b   Reid, Gregor ^c,d   Urbaniak, Camilla ^c,d   Byrne, William L ^a   Tangney, Mark ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZIRIDINE DERIVATIVE; CLADRIBINE; DEOXYCYTIDINE; FLUDARABINE; GEMCITABINE; TRETAZICAR; VIDARABINE;

ANALOGS AND DERIVATIVES; ANIMAL; BIOTRANSFORMATION; CANCER TRANSPLANTATION; COLONIC NEOPLASMS; DRUG EFFECTS; ESCHERICHIA COLI; FEMALE; GROWTH, DEVELOPMENT AND AGING; INTRALESIONAL DRUG ADMINISTRATION; LISTERIA; METABOLISM; MICROBIOLOGY; MOUSE; PATHOLOGY; SKIN; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; BIOTRANSFORMATION; CLADRIBINE; COLONIC NEOPLASMS; DEOXYCYTIDINE; ESCHERICHIA COLI; FEMALE; INJECTIONS, INTRALESIONAL; INJECTIONS, SUBCUTANEOUS; LISTERIA; MICE; NEOPLASM TRANSPLANTATION; SKIN; TREATMENT OUTCOME; VIDARABINE;

EID: 84942847425     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14554     Document Type: Article

References (54)

1. Cummins, J., Tangney, M. Bacteria and tumours: causative agents or opportunistic inhabitants? Infectious agents and cancer 8, 11, doi: 10.1186/1750-9378-8-11 (2013).
2. Zambirinis, C. P., Pushalkar, S., Saxena, D., Miller, G. Pancreatic cancer, inflammation, and microbiome. Cancer journal 20, 195-202, doi: 10.1097/PPO.0000000000000045 (2014).
3. Cummins, J., Cronin, M., van Pijkeren, J. P., Gahan, C. G., Tangney, M. Bacterial systems for gene delivery to systemic tumors. Methods in molecular biology 1141, 201-209, doi: 10.1007/978-1-4939-0363-4-13 (2014).
4. Viaud, S. et al. Gut microbiome and anticancer immune response. Cell death and differentiation, doi: 10.1038/cdd.2014.56 (2014).
5. Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971-976, doi: 10.1126/science.1240537 (2013).
6. Tangney, M., Gahan, C. G. Listeria monocytogenes as a vector for anti-cancer therapies. Current gene therapy 10, 46-55 (2010).
7. Morrissey, D., O'Sullivan, G. C., Tangney, M. Tumour targeting with systemically administered bacteria. Current gene therapy 10, 3-14 (2010).
8. Roberts, N. J. et al. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Science translational medicine 6, 249-111, doi: 10.1126/scitranslmed.3008982 (2014).
9. Bettegowda, C. et al. The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT. Nature biotechnology 24, 1573-1580, doi: 10.1038/nbt1256 (2006).
10. Urbaniak, C. et al. Microbiota of human breast tissue. Applied and environmental microbiology 80, 3007-3014, doi: 10.1128/AEM.00242-14 (2014).
11. Xuan, C. et al. Microbial dysbiosis is associated with human breast cancer. PloS one 9, e83744, doi: 10.1371/journal.pone.0083744 (2014).
12. Bonnet, M. et al. Colonization of the human gut by E. coli and colorectal cancer risk. Clinical cancer research: an official journal of the American Association for Cancer Research 20, 859-867, doi: 10.1158/1078-0432.CCR-13-1343 (2014).
13. Flanagan, L. et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology 33, 1381-1390, doi: 10.1007/s10096-014-2081-3 (2014).
14. McCoy, A. N. et al. Fusobacterium is associated with colorectal adenomas. PloS one 8, e53653, doi: 10.1371/journal.pone.0053653 (2013).
15. Arora, P. K., Jain, R. K. Biotransformation of 4-chloro-2-nitrophenol into 5-chloro-2-methylbenzoxazole by a marine Bacillus sp. strain MW-1. Biodegradation 23, 325-331, doi: 10.1007/s10532-011-9512-y (2012).
16. Nassar, A. F. in Biotransformation and Metabolite Elucidation of Xenobiotics 163-216 (John Wiley & Sons, Inc., 2010).
17. Helsby, N. A., Ferry, D. M., Patterson, A. V., Pullen, S. M., Wilson, W. R. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. British journal of cancer 90, 1084-1092, doi: 10.1038/sj.bjc.6601612 (2004).
18. Cronin, M. et al. High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting. PloS one 7, e30940, doi: 10.1371/journal.pone.0030940 (2012).
19. Cronin, M. et al. Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors. Molecular therapy: the journal of the American Society of Gene Therapy 18, 1397-1407, doi: 10.1038/mt.2010.59 (2010).
20. Human Microbiome Project, C. Structure, function and diversity of the healthy human microbiome. Nature 486, 207-214, doi: 10.1038/nature11234 (2012).
21. Haiser, H. J., Turnbaugh, P. J. Is it time for a metagenomic basis of therapeutics? Science 336, 1253-1255, doi: 10.1126/science.1224396 (2012).
22. Aagaard, K. et al. The placenta harbors a unique microbiome. Science translational medicine 6, 237-265, doi: 10.1126/scitranslmed.3008599 (2014).
23. Coley, W. Late results of the treatment of inoperable sarcoma by the mixed toxins of Erysipelas and Bacillus prodigosus. Am J Med Sci 131, 375-430 (1906).
24. Glover, T. Progress in Cancer Research. Canada Lancet and Practitioner 67, 161-216 (1926).
25. Patschan, O. et al. Use of bacillus Calmette-Guerin in stage T1 bladder cancer: Long-term observation of a population-based cohort. Scandinavian journal of urology 49, 127-132, doi: 10.3109/21681805.2014.968868 (2015).
26. Nguyen, A., Heil, E., Patel, N., Duffy, A., Gilmore, S. A single-center evaluation of the risk for colonization or bacteremia with piperacillin-tazobactam-and cefepime-resistant bacteria in patients with acute leukemia receiving fluoroquinolone prophylaxis. Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners, doi: 10.1177/1078155214567161 (2015).
27. Kaspera, R. et al. Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo. Biochemical pharmacology, doi: 10.1016/j.bcp.2014.06.020 (2014).
28. Konig, C., Simmen, H. P., Blaser, J. Bacterial concentrations in pus and infected peritoneal fluid-implications for bactericidal activity of antibiotics. J Antimicrob Chemother 42, 227-232 (1998).
29. Kelly, S. L., Lamb, D. C., Jackson, C. J., Warrilow, A. G., Kelly, D. E. The biodiversity of microbial cytochromes P450. Adv Microb Physiol 47, 131-186 (2003).
30. Vredenburg, G. et al. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants. Toxicology letters 232, 182-192, doi: 10.1016/j.toxlet.2014.11.005 (2014).
31. Minton, N. P., Atkinson, T., Sherwood, R. F. Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida. J Bacteriol 156, 1222-1227 (1983).
32. Boghigian, B. A., Salas, D., Ajikumar, P. K., Stephanopoulos, G., Pfeifer, B. A. Analysis of heterologous taxadiene production in K-and B-derived Escherichia coli. Applied microbiology and biotechnology 93, 1651-1661, doi: 10.1007/s00253-011-3528-4 (2012).
33. Sorscher, E. J., Hong, J. S., Allan, P. W., Waud, W. R., Parker, W. B. In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase. Cancer chemotherapy and pharmacology 70, 321-329, doi: 10.1007/s00280-012-1908-9 (2012).
34. Chen, G. et al. Tumor-targeting Salmonella typhimurium, a natural tool for activation of prodrug 6MePdR and their combination therapy in murine melanoma model. Applied microbiology and biotechnology 97, 4393-4401, doi: 10.1007/s00253-012-4321-8 (2013).
35. Westman, E. L. et al. Bacterial inactivation of the anticancer drug doxorubicin. Chemistry & biology 19, 1255-1264, doi: 10.1016/j. chembiol.2012.08.011 (2012).
36. Tai, C. K. et al. Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene. Cancer gene therapy 17, 614-623, doi: 10.1038/cgt.2010.17 (2010).
37. Leist, T. P. et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. The Lancet. Neurology 13, 257-267, doi: 10.1016/S1474-4422(14)70005-5 (2014).
38. Robak, P., Robak, T. Older and new purine nucleoside analogs for patients with acute leukemias. Cancer treatment reviews 39, 851-861, doi: 10.1016/j.ctrv.2013.03.006 (2013).
39. Sousa, T. et al. The gastrointestinal microbiota as a site for the biotransformation of drugs. International journal of pharmaceutics 363, 1-25, doi: 10.1016/j.ijpharm.2008.07.009 (2008).
40. Haiser, H. J., Turnbaugh, P. J. Developing a metagenomic view of xenobiotic metabolism. Pharmacological research: the official journal of the Italian Pharmacological Society 69, 21-31, doi: 10.1016/j.phrs.2012.07.009 (2013).
41. Alimonti, A. et al. New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer treatment reviews 30, 555-562, doi: 10.1016/j.ctrv.2004.05.002 (2004).
42. Gandhi, M., Brieva, J. C., Lacouture, M. E. Dermatologic infections in cancer patients. Cancer treatment and research 161, 299-317, doi: 10.1007/978-3-319-04220-6-10 (2014).
43. Hagymasi, K., Tulassay, Z. infection: New pathogenetic and clinical aspects. World journal of gastroenterology: WJG 20, 6386-6399, doi: 10.3748/wjg.v20.i21.6386 (2014).
44. Pierantozzi, M. et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 66, 1824-1829, doi: 10.1212/01.wnl.0000221672.01272.ba (2006).
45. Marin, M., Gudiol, C., Garcia-Vidal, C., Ardanuy, C., Carratala, J. Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center. Medicine 93, 143-149, doi: 10.1097/MD.0000000000000026 (2014).
46. Olsina, M. et al. [Isolation of Haemophilus spp. from samples of pleural fluid: 11 years' review]. Enfermedades infecciosas y microbiologia clinica 12, 235-240 (1994).
47. Han, X. H. et al. Clostridium difficile infection in hospitalized cancer patients in Beijing, China is facilitated by receipt of cancer chemotherapy. Anaerobe 24, 82-84, doi: 10.1016/j.anaerobe.2013.05.004 (2013).
48. Skinner, E. C. et al. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin. The Journal of urology 190, 1200-1204, doi: 10.1016/j.juro.2013.04.031 (2013).
49. Houghton, B. B. et al. Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU international 111, 977-983, doi: 10.1111/j.1464-410X.2012.11390.x (2013).
50. Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W., Vogelstein, B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proceedings of the National Academy of Sciences of the United States of America 98, 15155-15160, doi: 10.1073/pnas.251543698 (2001).
51. Jia, L. J. et al. Tumor-targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose and low-dose metronomic regimens in a murine melanoma model. Int J Cancer 121, 666-674, doi: 10.1002/ijc.22688 (2007).
52. Valle, A., Le Borgne, S., Bolivar, J., Cabrera, G., Cantero, D. Study of the role played by NfsA, NfsB nitroreductase and NemA flavin reductase from Escherichia coli in the conversion of ethyl 2-(2?-nitrophenoxy)acetate to 4-hydroxy-(2H)-1,4-benzoxazin-3(4H)-one (D-DIBOA), a benzohydroxamic acid with interesting biological properties. Applied microbiology and biotechnology 94, 163-171, doi: 10.1007/s00253-011-3787-0 (2012).
53. Somers, K. D. et al. Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy. Int J Cancer 107, 773-780, doi: 10.1002/ijc.11464 (2003).
54. Ahmad, S., Casey, G., Sweeney, P., Tangney, M., O'Sullivan, G. C. Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Molecular therapy: the journal of the American Society of Gene Therapy 17, 1101-1108, doi: 10.1038/mt.2009.66 (2009).